Navigation Links
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
Date:9/26/2008

LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously announced promising data from its 8-week, placebo controlled, double-blind, multi-center Phase II trial in patients with persistent stuttering which showed that pagoclone produced a statistically significant benefit in multiple primary and secondary stuttering endpoints compared to placebo. Pagoclone is a novel member of the cyclopyrrolone class of compounds and acts as a gamma amino butyric acid (GABA) selective receptor modulator.

Under the terms of the Agreement, which is subject to applicable regulatory clearances and customary conditions, Indevus will conduct and Teva will reimburse Indevus for its expenses for a Phase IIb study. The placebo- controlled study will involve approximately 300 patients with stuttering in the U.S. treated for a period of six months and is expected to commence enrollment by Q1 2009.

Following the completion of a successful Phase IIb study, the Agreement provides for Indevus to participate on a 50/50 basis with Teva in the U.S., sharing development and marketing costs, and splitting future profits, in addition to receiving milestone payments. Under certain circumstances, either party may convert the Agreement from the 50/50 arrangement to a royalty structure where Teva will be responsible for all development and commercial costs in the U.S. and Indevus would receive royalties on net sales, in addition to milestones. In either case, if the arrangement continues, Teva will be responsible for the conduct of the Ph
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
2. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
3. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
4. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
5. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
6. Indevus Announces Submission of New Drug Application
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Clinton Global Initiative Announces BDs Commitment to Biamba Marie Mutombo Hospital
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
11. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Investor-Edge has initiated ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ... on these five companies can be accessed at: ... the NASDAQ Composite ended at 4,419.48, up 2.40%, the ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014   ... a world-renowned leader in the field of infertility, ... approach to embryonic screening. The research abstract, released ... for Reproductive Medicine (ASRM) meeting in ... (CCS) and single gene defect (SGD) pre-implantation genetic ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... Choosing the right doctor when opting for cosmetic procedures ... subsequent costs often become determining factors rather than the ... on the right questions to ask and often times ... treatment. However, Board Certified Dermatologists can offer a skilled, ...
... N.J., Sept. 16, 2011 Novartis announced today positive ... ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), ... presented at the 2011 European Pediatric Rheumatology Congress in ... the study were met[2]. Most ACZ885 patients ...
Cached Medicine Technology:Trust Your Derm: The JUVA Skin & Laser Center Advises Patients To Seek Board Certified Dermatologists and AAAHC Accredited Facilities For Safe Cosmetic Procedures 2Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 2Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 3Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 4Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 5Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 6
(Date:10/25/2014)... Hartford, CT (PRWEB) October 25, 2014 Background: ... for Addiction Recovery (CCAR). He is a pioneer in the ... 30-year career in Connecticut's state treatment system and when he ... had nagged him while in public service. ... are making critical decisions concerning them? , 2. Can ...
(Date:10/25/2014)... TX (PRWEB) October 25, 2014 ... Chinese Molecular Diagnostics Industry, 2009-2019 is a ... and Chinese Molecular Diagnostics industry. The report ... Diagnostics including its classification, application and manufacturing ... China’s top manufacturers of Molecular Diagnostics listing ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Researchers who discovered ... findings are cause for concern. The use ... raised for human consumption contribute to the development ... to background information from the study. Each ... about 2 million people and kill about 23,000, ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... , CHICAGO , Jan. 26 ... a urologist tendered his $1-million insurance policy on January 20, ... deceased man arising out of the physician,s failure to timely diagnose bladder cancer. ... (Case no. 06 L 3887), Carmen Russell and Daniel Russell, ...
... , LITTLE FALLS, N.J. , ... provider of real-time, 24/7 medical news coverage and Continuing Medical ... from the American Academy of Family Physicians (AAFP) to offer ... physicians must have a broad understanding of many different diseases ...
... Jan. 26 President Obama will need several props ... including lifejackets, a box of teabags, a paper shredder, and a ... the address by taking the 2,074 page Senate health bill and ... the public a 20-page bill in plain, honest English," says ...
... January 26, 2010-- It,s known that people who live or ... die from serious injuries compared to those in more urban ... these higher mortality rates, new research suggests that limited access ... may be a factor. Researchers from St. Michael,s in ...
... recent case study by doctors at Mount Sinai Hospital ... transplant tourism, an offshoot of medical tourism, which focuses ... frown on the practice of transplant tourism where patients ... Philippines for their transplantation. These transplant tourists may ...
... ... ... National Heart Month, and Oldways and the Mediterranean Foods Alliance offer ... the Mediterranean region. Thousands of scientific studies (and the American Heart Association!) declare the Mediterranean ...
Cached Medicine News:Health News:Romanucci & Blandin, LLC, Reaches $1 Million Settlement in Medical Negligence Lawsuit 2Health News:MedPage Today(R) Approved to Offer AAFP Credit for Its News-Based Continuing Medical Education Activities 2Health News:MedPage Today(R) Approved to Offer AAFP Credit for Its News-Based Continuing Medical Education Activities 3Health News:Props for the President at His State of the Union Address 2Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 2Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 3Health News:Transplant tourism poses ethical dilemma for US doctors 2Health News:Transplant tourism poses ethical dilemma for US doctors 3Health News:10 Healthy Med Ways to Show Your Heart Some Love 2Health News:10 Healthy Med Ways to Show Your Heart Some Love 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: